Cardiome Announces Management Transition


    VANCOUVER, Aug. 3 /CNW/ - Cardiome Pharma Corp. (NASDAQ:   CRME / TSX: COM)
today announced that Doug Janzen, formerly President and Chief Business
Officer, has been appointed to the role of President and Chief Executive
Officer by the Board of Directors, effective immediately. Bob Rieder, formerly
Chairman and Chief Executive Officer, has been appointed Executive Chairman of
the Board.
    "My tenure as CEO has been very satisfying in terms of what we have
together accomplished, and I am honoured to have worked closely with so many
talented professionals at Cardiome," stated Mr. Rieder. "I am excited about
our future as I pass the reigns over to Doug Janzen, and I look forward to
working with my fellow Board members and the management team as we continue to
build value for Cardiome shareholders."
    "Having successfully led Cardiome through more than a decade of growth
and transformation, Bob has implemented a thoughtful and deliberate succession
process," said Richard Glickman, lead independent director of Cardiome's Board
of Directors. "The Board is highly confident that this re-alignment of
responsibilities will shepherd in a new chapter in Cardiome's evolution as a
world-class drug development company."
    "I am honoured to have the opportunity to lead this exceptional
organization. We have a fantastic group of dedicated and skilled employees at
Cardiome who have succeeded despite the many challenges faced over the past
few years, and I am excited about our prospects going forward." stated Mr.
Janzen. "I have worked closely with Bob over the past 6 years and look forward
to continuing our joint efforts to build Cardiome through this transition and
beyond. I want to thank him for his dedication and tremendous contribution to
Cardiome, and I wish him well in this next phase of his Cardiome career."
    Mr. Rieder, 63, became CEO of Cardiome in March 1998 and Chairman in
March 2007. Mr. Janzen, 40, joined Cardiome as Chief Financial Officer in
January 2003, and was appointed President and Chief Business Officer in March
2006, at which time he joined the Board of Directors of Cardiome.

    About Cardiome Pharma Corp.

    Cardiome Pharma Corp. is a product-focused drug development company
dedicated to the advancement and commercialization of novel treatments for
disorders of the heart and circulatory system. Cardiome is traded on the
NASDAQ National Market (CRME) and the Toronto Stock Exchange (COM). For more
information, please visit our web site at

    Forward-Looking Statement Disclaimer

    Certain statements in this press release contain forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995 or forward-looking information under applicable Canadian securities
legislation that may not be based on historical fact, including without
limitation statements containing the words "believe", "may", "plan", "will",
"estimate", "continue", "anticipate", "intend", "expect" and similar
expressions. Such forward-looking statements or information involve known and
unknown risks, uncertainties and other factors that may cause our actual
results, events or developments, or industry results, to be materially
different from any future results, events or developments expressed or implied
by such forward-looking statements or information. Such factors include, among
others, our stage of development, lack of product revenues, additional capital
requirements, risk associated with the completion of clinical trials and
obtaining regulatory approval to market our products, the ability to protect
our intellectual property, dependence on collaborative partners and the
prospects for negotiating additional corporate collaborations or licensing
arrangements and their timing. Specifically, certain risks and uncertainties
that could cause such actual events or results expressed or implied by such
forward-looking statements and information to differ materially from any
future events or results expressed or implied by such statements and
information include, but are not limited to, the risks and uncertainties that:
we may not be able to successfully develop and obtain regulatory approval for
vernakalant (iv) or vernakalant (oral) in the treatment of atrial fibrillation
or any other current or future products in our targeted indications; our
future operating results are uncertain and likely to fluctuate; we may not be
able to raise additional capital; we may not be successful in establishing
additional corporate collaborations or licensing arrangements; we may not be
able to establish marketing and sales capabilities and the costs of launching
our products may be greater than anticipated; we rely on third parties for the
continued supply and manufacture of vernakalant (iv) and vernakalant (oral)
and we have no experience in commercial manufacturing; we may face unknown
risks related to intellectual property matters; we face increased competition
from pharmaceutical and biotechnology companies; and other factors as
described in detail in our filings with the Securities and Exchange Commission
available at and the Canadian securities regulatory authorities at Given these risks and uncertainties, you are cautioned not to
place undue reliance on such forward-looking statements and information, which
are qualified in their entirety by this cautionary statement. All
forward-looking statements and information made herein are based on our
current expectations and we undertake no obligation to revise or update such
forward-looking statements and information to reflect subsequent events or
circumstances, except as required by law.

For further information:

For further information: Peter K. Hofman, Senior Director, Investor
Relations, (604) 676-6993 or Toll Free: 1-800-330-9928, Email:

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890